Search
News
Earnings
Castle Biosciences Q3 2026 Earnings: TissueCypher Growth Drives 24% Revenue Gain
Castle Biosciences reported Q3 2026 revenue of $102.9 million, up 24% year over year, as TissueCypher test volume climbed 47% while several dermatology tests posted softer volumes. Gross margin was stable and adjusted EBITDA improved, although the GAAP net loss widened because equity securities moved from a gain to a loss. The company raised full-year revenue guidance to $385 million–$395 million and maintained its expectation for positive adjusted EBITDA in Q4 and full-year 2026. Core operating leverage improved, but cash conversion and sustained GAAP profitability remain key areas to monitor.
TradingKey
Thu, Nov 5
Earnings
Genpact Q3 2026 Earnings: Advanced Technology Growth Drives Revenue
Genpact’s Q3 2026 revenue rose 7.3% year over year to $1.385 billion, while diluted EPS increased 7.2% to $0.89 and adjusted diluted EPS grew 10.3% to $1.07. Advanced Technology Solutions revenue surged 30.3% to $405 million, offsetting flat Core Business Services revenue, and gross margin expanded to 38.0%. The company raised its full-year gross margin outlook to about 36.9% and adjusted EPS growth guidance to at least 13%, though year-to-date operating cash flow fell to $142 million as receivables and other operating assets consumed cash.
TradingKey
Thu, Nov 5
Earnings
ICF Q3 2026 Earnings: Margin Expansion Lifts EPS on Modest Revenue Growth
ICF’s Q3 2026 revenue rose 1.1% year over year to $470.5 million, while GAAP diluted EPS increased to $1.76 from $1.28 and non-GAAP EPS climbed 18.6% to $1.98. Operating margin expanded 100 basis points to 9.3%, supported by efficient contract delivery and a favorable mix, even as commercial energy activity came in below management’s expectations. Federal revenue improved sequentially but remained lower year over year. ICF now expects full-year revenue to be similar to 2025 while maintaining its non-GAAP EPS guidance midpoint of $7.10.
TradingKey
Thu, Nov 5
Earnings
Astrana Health Q3 2026 Earnings: Operating Profit More than Doubles
Astrana Health (NASDAQ: ASTH) reported Q3 2026 revenue of $1,023.6 million, up 7% year over year, and diluted EPS of $0.26 versus $0.01. Operating income more than doubled to $39.9 million, while adjusted EBITDA rose 13% to $77.2 million as Care Partners led the quarter. The GAAP earnings increase was much larger than the 4% rise in adjusted EPS, and nine-month operating cash flow remained nearly flat. Full-year revenue, adjusted EBITDA, and free cash flow guidance was narrowed, with new Q4 ranges also provided.
TradingKey
Thu, Nov 5
Earnings
Solventum Q3 2026 Earnings: ERP Cutover Weighs on Sales as EPS Outlook Rises
Solventum’s Q3 2026 revenue fell 7.0% year over year to $1.949 billion, while organic sales declined 2.8% as the reversal of ERP-related advance orders reduced growth by 630 basis points. Adjusted diluted EPS decreased 3.6% to $1.45, and GAAP diluted EPS was $(0.07), reflecting restructuring, separation costs and a difficult comparison with the prior-year business-sale gain. Operating cash flow improved to $177 million. Solventum raised full-year adjusted EPS guidance to $7.20-$7.30 and expects organic growth toward the high end of its +2.5% to +3.0% range.
TradingKey
Thu, Nov 5
Earnings
Lionsgate Fiscal Q2 2027 Earnings: Studio Growth Restores Operating Profit
Lionsgate’s fiscal Q2 2027 revenue rose 41% year over year to $668.8 million, while diluted GAAP loss per share narrowed to $0.05 from $0.39. Operating income reached $29.1 million versus a $46.0 million loss, and adjusted OIBDA increased to $72.0 million. Motion Picture revenue grew 30%, while Television Production revenue rose 56% on higher scripted episodic deliveries. Despite the operating recovery, interest expense kept continuing operations in a net loss, and quarterly operating cash flow remained negative at $52.7 million.
TradingKey
Thu, Nov 5
Earnings
PRA Group Q3 2026 Earnings: Cost Cuts Lift Efficiency as Revenue Falls
PRA Group’s Q3 2026 revenue fell about 8% year over year to $286.3 million, while diluted EPS improved to $0.39 from a $10.43 loss that included a $412.6 million goodwill impairment. Portfolio income rose 5% to $270.8 million, but lower changes in expected recoveries reduced total portfolio revenue. Adjusted operating expenses declined 6% to $200.4 million, lifting adjusted cash efficiency to 63%, although adjusted EPS fell from $0.53. Cash collections were $535.6 million, and estimated remaining collections reached $8.8 billion.
TradingKey
Thu, Nov 5
Earnings
Cryoport Q3 2026 Earnings: Revenue Rises 14% as Adjusted EBITDA Turns Positive
Cryoport’s Q3 2026 revenue rose 14% to $50.2 million, led by 18% growth in Life Sciences Services and 25% growth in BioStorage/BioServices. Adjusted EBITDA from continuing operations turned positive at $1.1 million, but the GAAP net loss widened to $10.9 million and loss per share increased to $0.25 as other income swung to expense. Total gross margin slipped to 47.5%. Cryoport raised full-year revenue guidance to $197 million–$199 million and ended the quarter with $393.1 million in cash, equivalents, and short-term investments.
TradingKey
Thu, Nov 5
Earnings
Artivion Q3 2026 Earnings: Revenue Rises as Profitability Weakens
Artivion’s Q3 2026 revenue rose 9% to $123.8 million, but GAAP diluted EPS swung to a $0.16 loss from a $0.13 profit a year earlier. Adjusted EBITDA fell 8% to $22.5 million, while quarterly free cash flow turned negative at $17.6 million as product costs, operating expenses, interest expense, and capital spending increased. On-X and aortic stent grafts led product growth. Artivion narrowed full-year revenue guidance to $484 million–$492 million and adjusted EBITDA guidance to $93 million–$98 million, leaving both range midpoints essentially unchanged.
TradingKey
Thu, Nov 5
Earnings
OUTFRONT Media Q3 2026 Earnings: Transit Leads as Billboard Margins Narrow
OUTFRONT Media’s Q3 2026 revenue rose 9.3% year over year to $511.1 million, while diluted EPS increased to $0.36 from $0.29. Net income attributable to OUTFRONT climbed 26.3% to $64.8 million, but adjusted OIBDA grew more slowly as SG&A expenses rose faster than sales. Transit was the main profit driver, while billboard adjusted OIBDA was nearly flat and its margin declined. The quarter therefore showed stronger demand but uneven operating leverage across the company’s two main segments during the period.
TradingKey
Thu, Nov 5
Earnings
Ginkgo Bioworks Q3 2026 Earnings: Losses Narrow Despite a 6% Revenue Decline
Ginkgo Bioworks’ Q3 2026 revenue fell 6% year over year to $27.7 million, while GAAP net loss from continuing operations narrowed to $41.0 million from $73.4 million. Adjusted EBITDA improved to a $22 million loss from a $53 million loss as operating expenses declined. The company ended September with $285 million in cash, cash equivalents and marketable securities, reported $27 million of quarterly cash burn, and reaffirmed full-year cash-burn guidance of $125 million to $150 million. New autonomous-lab and Cloud Lab activity now needs to translate into sustained revenue growth.
TradingKey
Thu, Nov 5
Earnings
Alarm.com Q3 2026 Earnings: Revenue Rises While GAAP Profit Slips
Alarm.com’s Q3 2026 revenue rose 9.0% to $279.4 million, led by 9.0% growth in SaaS and license revenue to $191.2 million. GAAP diluted EPS increased to $0.66 from $0.65 even as GAAP net income eased to $34.3 million, while adjusted EBITDA climbed to $66.2 million. Operating margin expanded, but lower interest and other income limited bottom-line growth. The company raised full-year SaaS and license revenue guidance to $756.1 million-$756.3 million and adjusted EBITDA guidance to $227 million-$229 million.
TradingKey
Thu, Nov 5
Earnings
AEye Q3 2026 Results: Revenue Rises Tenfold While Net Loss Widens
AEye (NASDAQ: LIDR) reported Q3 2026 revenue of $506,000, up about tenfold from $50,000 a year earlier, while GAAP net loss widened to $11.2 million from $9.3 million. Diluted loss per share narrowed to $0.24 from $0.30 as the weighted average share count increased. Gross margin improved sequentially to negative 35% from negative 80%, supported by revenue mix, lower product costs, and lower warranty reserves. The company expects Q4 revenue of approximately $1 million and ended September with $63.1 million in cash, cash equivalents, and marketable securities.
TradingKey
Thu, Nov 5
Earnings
Entravision Q3 2026 Earnings: ATS Growth Drives Revenue Up 88%
Entravision’s Q3 2026 revenue rose 88% to $226.3 million, driven by a 133% increase in ATS net revenue to $177.2 million. Diluted EPS improved to $0.18 from a $0.11 loss, while operating income reached $28.3 million versus a $9.1 million loss a year earlier. Operating cash flow increased to $16.1 million, although the company’s implied gross margin narrowed as the lower-gross-margin ATS business became a larger part of the revenue mix. Media revenue grew 10%, helped by political advertising and retransmission fees.
TradingKey
Thu, Nov 5
Earnings
Puma Biotechnology Q3 2026 Earnings: NERLYNX Growth Offset by Higher Costs
Puma Biotechnology’s Q3 2026 revenue rose about 1.1% to $55.1 million as NERLYNX net product revenue increased 4.2% to $54.1 million. GAAP diluted EPS fell to $0.11 from $0.17, and net income declined to $6.0 million as cost of sales and R&D spending increased, while operating cash flow improved to $14.6 million. U.S. demand supported product sales, but a royalty estimate adjustment and delayed ex-U.S. partner sales limited growth. Puma raised full-year net income guidance to $20 million-$22 million.
TradingKey
Thu, Nov 5
Earnings
SUI Group Q3 2026 Earnings: Digital Asset Gains Drive $47.7 Million Net Income
SUI Group (NASDAQ: SUIG) reported Q3 2026 GAAP revenue of $311,000, down from $1.01 million a year earlier, while diluted EPS improved to $0.59 from a $0.72 loss. Net income reached $47.7 million, driven mainly by $82.7 million of unrealized gains on digital assets and receivables, partly offset by $28.0 million of realized trading losses. As of November 2, the company held 109.3 million SUI, including loan receivables, with most tokens staked at an approximately 1.5% annualized yield during the quarter.
TradingKey
Thu, Nov 5
Market Movers
Toronto-Dominion Bank Stock (TD) Closed Down by 3.99% on Nov 5: Drivers Behind the Movement
• Toronto-Dominion Bank faced selling pressure due to credit and margin concerns. • Regulatory remediation constraints and operational expenses continue inhibiting balance sheet expansion. • The stock reported an annual revenue of $34.67B and net profit of $14.31B.
Market Movers
Ge Vernova Inc Stock (GEV) Closed Down by 7.48% on Nov 5: What Signal Does It Send?
• GE Vernova faced selling pressure due to AI infrastructure regulatory and policy uncertainties. • Institutional portfolio adjustments and analyst price target reductions weighed on market sentiment. • Renewable portfolio operational friction and margin headwinds exacerbated the stock's decline.
TradingKey
Thu, Nov 5
Featured Tools
Top News
DomoAI Launches InkoAI Agent - One Sentence to Ready-to-Post Video
US October PPI Preview: Fed Rate Hike Expectations Rise, PPI May Be Key Variable; How Will US Stocks, Dollar, and Gold Move?
Gold Price Forecast: Gold Tumbles Below $3,900 as Trump Says No Need for Iran Deal; Can October PPI Spur a Rebound?
【US Pre-Market】Nvidia Rebounds Over 2%; Microsoft Falls Over 2% Amid Massive Global Outage; October PPI Due
Cisco Stock Retests $101.60 Ahead of Q1 Results, With AI Orders in Focus
